... elevation acute coronary syndrome Statins Low-density lipoprotein Mortality Octogenarians Frailty Visual Abstract Visual Abstract. © 2019 S. Karger AG, Basel 2019 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated...

... of low levels of low-density lipoprotein cholesterol (LDL-c) on cardiac mortality in a cohort of elderly patients with moderate and severe HF. Methods: Chronic HF patients from the HF Unit at the Tel-Aviv Medical Center (n = 212, 77% males) with an average NYHA classification of 2.8, a mean age of 76.9...

... total cholesterol, low-density lipoprotein (LDL) cholesterol, very-low-density lipoprotein (VLDL) cholesterol and triglyceride levels in patients with hyperlipoproteinemia or familial hypercholesterolemia. These lipoprotein changes have been associated with a regression of tendon xanthoma...

...David H. Blankenhorn 12 11 2008 Atherosclerosis, angiographic assessment Lipid-lowering therapy Coronary heart disease Plasma cholesterol levels, reduction Low-density lipoprotein 1989 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part...

... decrease in very-low-density lipoprotein (VLDL) cholesterol levels (p < 0.01) and a rise in high-density lipoprotein (HDL) cholesterol levels (p < 0.01) in 227 subjects with both type IIa and IIb hyperlipidemias. Low-density lipoprotein (LDL) cholesterol levels also fell: 20.3% in type IIa and 6...

... the low-density-lipoprotein-lowering effect of probucol appears quite variable. The use of low doses of bile acid sequestrants (4–8 g/day of cholestyramine or 5–10 g/day of colestipol) in combination with lovastatin, simvastatin, or probucol provides a therapeutic regimen that is usually well tolerated...

... treatment also decreased very low-density lipoprotein (VLDL) TG, total cholesterol and VLDL cholesterol, and increased high-density lipoprotein levels. Adverse effects of fenofibrate were minimal compared with placebo and resolved when the drug was discontinued. Overall, fenofibrate was found...

..., reducing the total cholesterol level by 20–25% in type Ha patients and triglycerides by 40–60% in type lib and IV patients. High levels of low-density lipoprotein cholesterol are reduced and, where low at baseline, high-density lipoprotein levels are increased. An associated activity is a 10–28% reduction...

... phosphatase, cholesterol 7α-hydroxylase, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase. Activation of phosphatidic acid phosphatase promotes hepatic triglyceride (TG) synthesis, induces secretion of TG-rich, very low density lipoprotein particles, and consequently, increases plasma TG levels...

...John LaRosa Both alone and in combination with other lipid-lowering drugs, the bile acid sequestrants cholestyramine and colestipol, are excellent agents for lowering circulating low-density lipoprotein (LDL) cholesterol levels. They have been shown to lower the incidence of new coronary events...

... nightly (n=17) or gemfibrozil 600 mg twice daily (n=8), and in stratum 2 (cholesterol levels ≧ 7.8 mmol/l [≧ 302 mg/dl]), patients received either lovastatin 40 mg nightly (n=23) or gemfibrozil 600 mg b.i.d. (n=19) for 6 weeks. Low-density lipoprotein (LDL) cholesterol levels were reduced significantly...

...Conrad B. Blum; Robert I. Levy A large and convincing body of evidence links increased coronary risk with elevated plasma levels of low-density lipoprotein (LDL) cholesterol. Cholesterol in atherosclerotic lesions originates from that circulating in the blood bound to LDL. Even mild degrees...

... effective at lowering levels of low-density lipoprotein cholesterol (LDL-C). New formulations of drugs such as nicotinic acid can improve treatment regimens and reduce unpleasant side-effects, thereby improving patient compliance with this therapy. In terms of developing novel drugs, the introduction...